Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes

Trial Profile

Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2019

At a glance

  • Drugs Insulin aspart (Primary) ; Insulin detemir
  • Indications Type 1 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms Onset 1
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 01 Jun 2019 Post hoc analysis of Onset 1 and Onset 8 trial published in the Diabetes Therapy.
    • 07 Nov 2018 Results of a post hoc analysis of NCT01618188, NCT02003677, NCT01934712, NCT02568280 and NCT01831765 assessing the PK of fast-acting Insulin Aspart versus free Insulin Aspart, published in the Clinical Pharmacokinetics
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top